BIF002

BIF002 is a **bispecific T cell engager** (TCE) designed to simultaneously bind **interleukin-1 receptor accessory protein (IL1RAP)** on leukemic cells and **CD3** on T cells, thereby redirecting and activating T cells to selectively kill IL1RAP-positive acute myeloid leukemia (AML) cells, including leukemic stem cells (LSCs)[1][3][5][9]. The molecule is constructed using Fab arm exchange to yield an IgG-like molecule with high affinity for human IL1RAP and modest affinity for CD3, while incorporating mutations in the Fc domain to reduce FcγR binding and mitigate off-target effects[3][5]. Preclinical studies demonstrate potent AML cell lysis, enhanced T-cell activation and proliferation, and potent elimination of bulk AML blasts and LSCs, with no significant toxicity to normal bone marrow[1][3][5]. Developed by a collaboration between The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) and City of Hope, BIF002 represents a promising and selective immunotherapeutic approach for AML patients[1][3][5].

Other names

BIF002BIF-002BIF 002